Olpruva (Sodium Phenylbutyrate) Patent Expiration, LOE Window & CMS Spending
Olpruva (Sodium Phenylbutyrate) by Acer Therapeutics: FDA Orange Book LOE 2036-10-17, 3 AB generics, $488K 2024 CMS Part D & Medicaid spend, and $57,029 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Acer Therapeutics |
| FDA Application & Pathway | N214860 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2036-10-17 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $488K |
| 2024 Medicare Part D Spend | $488K |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($57,029 intro WAC) |